Role change
Tony J. Hunt
Executive Chair
RGEN ·
REPLIGEN CORP
Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors
Ready 8-Ks
47
Latest filing
July 28, 2026, 7:13 AM ET
Top materiality
0.90
Event mix
earnings ×21 · leadership ×10 · m_and_a ×6
Sentiment
19 pos · 7 neg · 21 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for RGEN
Highest-materiality recent filing
Repligen to acquire BioLife Solutions for ~$1.5B; reports preliminary Q2 revenue growth of ~12%
- Repligen to acquire BioLife for ~$1.5B; per share consideration $31.00 ($11.25 cash + 0.1442 RGEN shares).
- Deal expected to close Q4 2026; boards unanimously approved; subject to BLFS stockholder approval and HSR clearance.
-
Repligen Q2 revenue $204M (+13% organic), adj EPS $0.54; raises FY guidance; acquires BioLife
Q2 revenue $204M, +12% reported, +13% organic; adjusted EPS $0.54 vs $0.37 prior year.
-
Repligen to acquire BioLife Solutions for ~$1.5B; reports preliminary Q2 revenue growth of ~12%
Repligen to acquire BioLife for ~$1.5B; per share consideration $31.00 ($11.25 cash + 0.1442 RGEN shares).
-
Repligen 2026 annual meeting: all proposals pass; director Muir gets 25.7% against
All nine director nominees elected; Glenn P. Muir received highest opposition (13.3M against, 25.7% of votes cast).
-
Repligen Q1 revenue $194M (+11% organic); raises adjusted EPS guidance to $1.97-$2.05
Q1 revenue $194M, +15% reported/+11% organic; GAAP EPS $0.15, adjusted EPS $0.48 (+23% YoY).
-
Repligen Q4 revenue $198M (+18%); FY26 guidance $810-840M
Q4 revenue $198M, up 18% reported and 14% organic YoY; full year 2025 revenue $738M (+16% reported and organic non-COVID).
-
Repligen elects Martin D. Madaus as Chair, succeeding Tony Hunt effective Mar 13, 2026
Tony Hunt retires as Executive Chair and Board member effective March 13, 2026; will serve as advisor through March 2027.
-
Repligen Q3 revenue $189M (+22% YoY); raises FY2025 guidance to $729-737M
Revenue $189M, +22% reported, +18% organic; double-digit growth across all franchises.
-
Repligen appoints Violetta Hughes as Chief Accounting Officer, effective Sept 1, 2025
Replaces Jason K. Garland as principal accounting officer; Garland remains CFO focusing on strategy.
-
Repligen Q2 revenue $182M (+17% organic non-COVID); orders >20% YoY; raises FY guidance
Revenue $182M, up 15% reported and 17% organic non-COVID YoY.
-
Stockholders approved a Certificate of Amendment to limit officer liability under Delaware law (45.3M for, 5.9M against).
-
Repligen Q1 revenue $169M (+10% YoY); adjusted EPS $0.39 vs $0.30; orders up high-teens
Revenue $169M, up 10% reported, 14% organic non-COVID YoY; GAAP EPS $0.10, adjusted EPS $0.39.
-
Repligen Q4 revenue $168M; FY2024 $634M; guides FY2025 8-12% growth
Q4 revenue $168M, flat YoY; FY2024 revenue $634M vs $632M.
-
Repligen Q3 revenue $155M (+10% YoY); adjusted EPS $0.43 vs $0.23
GAAP net loss ($0.7M) vs income $17M; adjusted net income $24M vs $13M.
-
Restatement covers Q1'23 through Q2'24; $17.3M payment from cancelled COVID orders was mis-timed.
-
Repligen Q2 revenue $154M, adj. EPS $0.33, orders $157M; CEO transition, Tantti acquisition
Q2 2024 revenue $154M vs $159M prior year; GAAP EPS $0.06, adjusted EPS $0.33 vs $0.53.
-
Repligen reports unauthorized access to files on its information systems
Unauthorized third party accessed certain files on July 9, 2024; response procedures activated immediately.
-
Repligen appoints Olivier Loeillot as CEO effective Sept 1, 2024; Hunt becomes Executive Chair
Loeillot receives $750K base salary, 85% target bonus, and a $5M equity award (50% RSUs, 25% options, 25% PSUs).
-
Tony Hunt transitions from CEO to Executive Chair effective Sept 1, 2024; Olivier Loeillot named President and CEO.
-
Repligen shareholders elect all nine directors, ratify EY, approve say-on-pay at 2024 meeting
All nine director nominees elected with votes for ranging from ~45.95M to ~49.48M.
-
Repligen Q1 revenue falls 17% to $151M; GAAP EPS $0.04, adjusted EPS $0.28
Q1 revenue $151.3M, down from $182.7M YoY; GAAP net income $2.1M ($0.04 diluted EPS) vs $28.8M ($0.51).
-
Repligen appoints Maggie A. Pax to Board of Directors, expanding to nine members
Pax elected to board effective March 18, 2024; board expands from eight to nine members.
-
Repligen Q4 revenue down 16.6% to $155.7M; net loss $0.46/share
Q4 2023 revenue $155.7M vs $186.8M in Q4 2022; full year $638.8M vs $801.5M.
-
Repligen issues $600M of 1.00% convertible notes due 2028, exchanges ~$310M of 2024 notes
Issued $600M aggregate principal of 1.00% Convertible Senior Notes due 2028, with ~$309.9M exchanged for existing 0.375% 2024 notes and ~$290.1M cash.
-
Repligen issues $600M of 1% convertible notes due 2028, exchanges $217.7M of 2024 notes
Issues $600M aggregate 1.00% Convertible Senior Notes due 2028; $309.9M exchanged for $217.7M of 0.375% notes due 2024, $290.1M for cash.
-
Repligen Q3 revenue $141.2M (-30% YoY); narrows FY2023 outlook, sees order recovery
Total revenue $141.2M, base business $140.1M; GAAP EPS $0.32, adjusted EPS $0.23.
-
Repligen appoints Olivier Loeillot as President and CCO; Hunt remains CEO
Loeillot appointed President and Chief Commercial Officer effective Oct 2, 2023; reports to CEO Tony Hunt.
-
Repligen to acquire Metenova for cash and equity; adds magnetic mixing technology
Metenova projected FY2023 revenue $24-25M; ~50 employees; magnetic mixers for bioprocess.
-
Repligen appoints Jason K. Garland as CFO, replacing retiring Jon Snodgres
Garland (ex-Integer CFO) named CFO effective Sept 25, 2023; Snodgres remains advisor through Oct 6.
-
Repligen Q2 revenue down 23%; slashes FY2023 revenue guidance to $635-$665M
Q2 total revenue $159.2M (-23.3% YoY); base business revenue down 8.7%.
-
Eight directors elected including Tony J. Hunt; all nominees received majority support.
-
Repligen Q1 revenue $182.7M, down 12% YoY; cuts full-year guidance on macro headwinds
GAAP EPS $0.51 (down 37% YoY); adjusted EPS $0.64 (down 30% YoY); gross margin 55.2% (down 520 bps).
-
Repligen completes acquisition of FlexBiosys Inc. on April 17, 2023
Completed acquisition of all outstanding equity of FlexBiosys Inc. on April 17, 2023.
-
Repligen announces acquisition of FlexBiosys for undisclosed cash, equity, and earnout
Repligen executed Equity Purchase Agreement to acquire all outstanding equity of FlexBiosys.
-
Repligen Q4 revenue flat YoY at $186.8M; guides 2023 revenue down 5% to $760-800M
Q4 GAAP EPS $0.85 (up from $0.50 YoY); adjusted EPS $0.68 (down from $0.81).
-
Repligen appoints Martin D. Madaus to board; board expands to 8
Martin Madaus, Ph.D., joined Repligen's board effective Feb 6, 2023, also named to Nominating and Corporate Governance Committee.
-
Repligen Q3 revenue $200.7M (+13% YoY); raises FY revenue guidance to $795-$805M
Revenue $200.7M, +13% reported, +19% constant currency, +16% organic; base business up 29% YoY.
-
Repligen Q2 revenue $207.6M (+27% YoY); raises FY 2022 guidance
Q2 revenue $207.6M, up 27% as reported, 32% constant currency; organic growth 29%.
-
Repligen appoints Dr. Konstantin Konstantinov to board; all directors re-elected at annual meeting
Konstantinov elected to board effective May 26, 2022; brings 30 years of bioprocessing expertise from Genzyme and Bayer.
-
Repligen Q1 revenue $206.4M (+45% YoY); lowers FY2022 revenue guidance on COVID decline
Record Q1 revenue of $206.4M (+45% YoY); GAAP EPS $0.81, adjusted EPS $0.92.
-
Repligen elects combination settlement for convertible notes due 2024
Irrevocably elected Combination Settlement with $1,000 Specified Dollar Amount per $1,000 principal for 0.375% Convertible Senior Notes due 2024.
-
Repligen Q4 revenue $186.5M (+72% YoY); FY 2022 guidance $800-830M (19-24% growth)
Q4 revenue $186.5M (+72% YoY, organic +69%); GAAP EPS $0.50, adjusted EPS $0.81.
-
Repligen promotes James Bylund to Chief Operating Officer effective Jan 1, 2022
James Bylund promoted from SVP, Operations & IT to COO and principal operating officer, effective Jan 1, 2022.
-
Repligen acquires Bio-Flex Solutions and Newton T&M for cash; terms undisclosed
Acquired all outstanding equity interests in Bio-Flex Solutions and Newton T&M effective Dec 16, 2021.
-
Repligen Q3 revenue $178.2M (+89% YoY); raises FY 2021 revenue guidance to $655-665M
Revenue hit a record $178.2M in Q3 2021, up 89% YoY as reported and 77% organically.
-
Total consideration ~$150M, consisting of $75M cash and $75M in Repligen common stock, plus three-year earnout.
-
Repligen extends Cytiva supply agreement for ligand manufacture through 2025
Long-term supply agreement with Cytiva Sweden AB extended through 2025.
-
Repligen Q2 revenue $163M (+86% YoY); adj. EPS $0.79; raises FY21 outlook
Q2 revenue $163.0M, up 86% YoY as reported and 69% organic; base business grew 35% YoY.
Executive changes
Appointed
Olivier Loeillot
President and Chief Executive Officer
RGEN ·
REPLIGEN CORP
Repligen has appointed Olivier Loeillot, Repligen’s President and Chief Commercial Officer, to the role of President and Chief Executive Officer, as successor to Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors (the “Board”), with such transition to be effective September 1, 2024
Role change
Karen A. Dawes
Lead Independent Director
RGEN ·
REPLIGEN CORP
appointed Karen A. Dawes, the Board’s current Chair, to the role of Lead Independent Director
Appointed
Olivier Loeillot
Member of the Board
RGEN ·
REPLIGEN CORP
the Board elected Mr. Loeillot as a member of the Board
Appointed
Margaret A. Pax
Director
RGEN ·
REPLIGEN CORP
the Board elected Margaret A. Pax to the Board, effective immediately (the “Effective Date”).
Role change
Tony Hunt
President
RGEN ·
REPLIGEN CORP
In connection with Mr. Hunt’s and the rest of the Board’s appointment of Mr. Loeillot’s as President and Chief Commercial Officer, Mr. Hunt will relinquish his role of President, effective October 2, 2023.
Appointed
Olivier Loeillot
President and Chief Commercial Officer
RGEN ·
REPLIGEN CORP
On October 2, 2023, Repligen Corporation (the “Company”) announced that Olivier Loeillot would be joining the Company as its President and Chief Commercial Officer, effective October 2, 2023 (the “Effective Date”).
Departed
Jon Snodgres
Chief Financial Officer
RGEN ·
REPLIGEN CORP
replacing Jon Snodgres, who tendered his intention to retire on September 8, 2023 and who will continue in a full-time advisory role with the Company until October 6, 2023.
Appointed
Jason K. Garland
Chief Financial Officer
RGEN ·
REPLIGEN CORP
On September 12, 2023, Repligen Corporation (the “Company”) announced that Jason K. Garland would be joining the Company as its Chief Financial Officer, effective September 25, 2023 (the “Effective Date”), replacing Jon Snodgres, who tendered his intention to retire on September 8, 2023 and who will continue in a full-time advisory role with the Company until October 6, 2023.
Appointed
Martin Madaus
Director
RGEN ·
REPLIGEN CORP
the Board elected Martin Madaus, Ph.D. to the Board, effective February 6, 2023
Appointed
Konstantin Konstantinov
Director
RGEN ·
REPLIGEN CORP
the Board elected Konstantin Konstantinov, Ph.D. to the Board, effective May 26, 2022
Role change
James Bylund
Chief Operating Officer
RGEN ·
REPLIGEN CORP
On January 3, 2022, Repligen Corporation (the “ Company ”) promoted James Bylund, the Company’s current Senior Vice President, Operations and Information Technologies, to the role of Chief Operating Officer of the Company, effective January 1, 2022.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.70 · Most common event earnings